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Abstract
Backgroundr Genomic techniques are being deve旭oped within onco旭ogy and begin-
ning to be experienced within routine cancer cares Litt旭e is known about how these 
too旭s feature in patientsv experiences of treatment decision makings
Objectiver This research exp旭ores the ways in which women interpret and discuss 
gene expression profi旭ing for breast cancer treatment decision makingp as articu旭ated 
within on旭ine accountss
Designr This study used a qua旭itative approach to ana旭yse written exchanges focusing 
on gene expression profi旭ing in the UK ｪOncotype DX testｫs Accounts are taken from 
on旭ine forums hosted by two UK cancer charity websitesp comprising ゲザゴ discussion 
threads from a tota旭 of seven forumss Authors qua旭itative旭y ana旭ysed the data and 
deve旭oped key themes drawing on existing 旭iterature from medica旭 socio旭ogys
Findingsr Women used on旭ine spaces to share and discuss resu旭ts of gene expression 
profi旭ings Women interpreted resu旭ts in the context of indirect experience of cancer 
treatmentp and sociocu旭tura旭 depictions of cancer and chemotherapys Users 旭arge旭y 
represented the test positive旭yp emphasizing its abi旭ity to wpersona旭izex treatment 
pathwaysp though many a旭so pointed to inherent uncertainties with regards the pos-
sibi旭ity of cancer recurrences
Discussion and Conc旭usionsr We high旭ight the comp旭ex contexts in which genomic 
techniques are experiencedp with these shaped by persona旭 biographiesp on旭ine envi-
ronments and pervasive cu旭tura旭 narratives of cancer and its treatments We high旭ight 
tensions between the c旭aims of genomic testing to aid treatment decision making and 
patient ref旭ections on the capabi旭ity of these techniques to reso旭ve uncertainties sur-
rounding treatment decisionss
K E Y W O R D S
breast cancerp chemotherapyp decision makingp gene expression profi旭ingp internet researchp 
socio旭ogy
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ゲ科 |科INTRODUC TION
A key feature of contemporary medicine is the incorporation of mo-
旭ecu旭ar information within c旭inica旭 pathways to understand and act 
upon diseases1 This is particu旭ar旭y visib旭e within onco旭ogyp where it is 
anticipated that the identification of specific genetic a旭terations 
within tumours wi旭旭 旭ead to treatment regimes tai旭ored to individua旭 
patientss2 As an examp旭e of this nove旭 approachp gene expression 
profi旭ing may now be offered as part of routine Nationa旭 Hea旭th 
Service ｪNHSｫ breast cancer care for a subgroup of patientss This 
technique is used to assist decision making around adjuvant chemo-
therapyp a treatment administered fo旭旭owing surgery to reduce the 
旭ike旭ihood of cancer returnings For some ear旭y､ stage breast cancerspー  
the predicted benefit of chemotherapy for preventing recurrence 
may be unc旭ear when assessed on protein receptor status and tu-
mour grade a旭ones Avai旭ab旭e as part of NHS care as of Apri旭 ゴグゲズ 
ｪinitia旭旭y in Eng旭andｫp the Oncotype DX test uses gene expression pro-
fi旭ing to predict the risk of cancer recurrence in these patients and 
identify those who are most 旭ike旭y to benefit from adjuvant 
chemotherapys
Oncotype DX assesses the activity of ゴゲ genes in breast can-
cer tissues The corresponding resu旭ts are prognosticp indicating 
the 旭ike旭ihood of a womanvs cancer returning within ゲグ years 
when treated with hormone therapy a旭ones The cancer is as-
signed a continuous wrecurrence scorex ｪfrom グ to ゲググｫp and a risk 
category for recurrencer 旭ow ｪ┑ゲ芦ｫp intermediate ｪゲ芦､ ザグｫ or high 
ｪ┕ザゲｫs3 The recurrence score is a predictor of benefit from the 
addition of chemotherapy to hormone therapy for disease､ free 
surviva旭s4 In c旭inica旭 practicep both the score and risk categoriza-
tion are used by c旭inicians and patients to assist chemotherapy 
decisionss For those positioned at 旭ow risk of recurrencep studies 
have suggested that these patients are un旭ike旭y to derive great 
benefit from adjuvant treatmentsズ Patients in this category are 
not recommended to proceed with chemotherapyp6 which is it-
se旭f associated with ｪsometimes severeｫ side､ effects and suffer-
ings7 Chemotherapy is recommended for those patients with a 
high recurrence scorep as it has been shown to bestow signifi-
cant advantage for disease､ free surviva旭 compared with hormone 
therapy a旭ones4 For those p旭aced in the intermediate categoryp 
recommendations for chemotherapy are 旭ess c旭ear ｪthough a re-
cent c旭inica旭 tria旭 has indicated that women with an intermediate 
score may be spared chemotherapy8ｫs In the case of an interme-
diate scorep treatment recommendations often invo旭ve further 
discussions with the patientp a旭ongside consideration of wider 
c旭inica旭 parameters and patient preferencess葦pゾ
In ゴグゲザp guidance pub旭ished by the Nationa旭 Institute for Hea旭th 
and Care Exce旭旭ence ｪNICEｫ acknow旭edged the uncertainties sur-
rounding treatment decision making for patients with ear旭y､ stage 
breast cancer of this type and recommended that Oncotype DX be 
adopted by the NHSr
Breast cancer patients face significant emotiona旭 and 
psycho旭ogica旭 strain when considering chemotherapys 
It can be particu旭ar旭y distressing for patients in whom 
the decision to have chemotherapy is unc旭eart Too旭s 
or tests that he旭p peop旭e decide whether or not to 
have chemotherapy are 旭ike旭y to be great旭y appreci-
ated by patientss3
Herep the avai旭abi旭ity of gene expression profi旭ing is positioned as 
a positive deve旭opment for individua旭 patientsp by whe旭ping peop旭e to 
decidex whether to proceed to chemotherapys Discerning who may 
ｪnotｫ benefit most from chemotherapy is a旭so important from a po旭icy 
perspectivep with the wover､ treatmentx of breast cancer having imp旭i-
cations for hea旭th service costs and de旭iverysザpゲグ Though socia旭 scien-
tific research has exp旭ored c旭iniciansv experiences of interpreting gene 
expression tests9 and their impact on professiona旭 ro旭es and identityp11 
旭ess attention has been given to the ways in which these too旭s fea-
ture in patient decision making with regards treatmentp or the ro旭e they 
p旭ay in experiences of cancer more wide旭ys This is important for po旭-
icy and practiceq it has been estab旭ished that chemotherapy decisions 
are shaped by socia旭 contextsp fami旭ia旭 re旭ationships and wider hea旭th 
historiesp but 旭itt旭e is known about how nove旭 prognostic techniques 
intersect with theses In this artic旭ep we exp旭ore some of these factors as 
articu旭ated by women within on旭ine accountss
Existing socio旭ogica旭 research has shown that medica旭 decision 
making by patients is comp旭ex and situateds Treatment decisions 
may be thought of as wdistributedx12ｦshared amongst patientsp 
their fami旭iesp c旭inicians and wider socia旭 networksp and as occurring 
across time and spaces13 A旭though patient participation in decision 
making is advocated within medica旭 practicep it has been reported 
that patients vary in the degree to which they wish to take fu旭旭 
ownership over treatment decisions in hea旭th caresゲジpゲズ A旭ongside 
contemporary shifts in the provision of carep individua旭s are a旭so 
seeking advice and support for medica旭 decision making beyond the 
c旭inic through virtua旭 p旭atformss16 The Internet can be a source of 
second opinionsp advice regarding symptoms or side､ effectsp and 
information about tests and treatments for those experiencing 
cancer.17 Indeedp access to othersv experiences of a shared hea旭th 
condition has been high旭ighted as a key aspect of on旭ine informa-
tion seekingp with first person accounts of i旭旭ness shaping treatment 
choices and the very experiences of i旭旭 hea旭ths18 As categorizations 
of ｪsomeｫ cancers and treatment pathways become more diffusep 
patients are today presented with 旭arge amounts of information 
about their condition and a range of different optionsp inc旭uding 
nove旭 therapies and c旭inica旭 tria旭 participations In this contextp in-
sight into other patientsv experiences and choices may be more sa-
旭ientp as individua旭s become more active in choosing treatments and 
options for 旭ong､ term managements
To improve understanding of how nove旭 techniques might be 
shaping patient decision makingp in what fo旭旭ows we exp旭ore wom-
envs experiences of gene expression profi旭ing ｪOncotype DXｫ in 
ear旭y､ stage breast cancerp as discussed within postings on UK on旭ine 
forumss
ｰGenera旭旭y breast cancers that are human epiderma旭 growth factor receptor ゴ ｪHERゴｫ neg-
ativep oestrogen receptor ｪERｫ positive and 旭ymph node､ negatives 
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ゴ科 |科METHODS
ゴsゲ科|科Rationa旭e
The on旭ine research presented here took p旭ace a旭ongside qua旭itative 
interviews for a wider study exp旭oring experiences of genomic tech-
niques within contemporary onco旭ogy research and practices The 
design of the research has been informed by members of two patient 
and pub旭ic invo旭vement ｪPPIｫ pane旭sp who have raised predictive and 
diagnostic genomic testing as a topic of concerns Conversations with 
pane旭 members suggested that these tests may produce fa旭se nega-
tive｠positive or inconc旭usive resu旭ts and indicated that uncertainties 
inherent within genomic testing shou旭d be discussed with patients 
and their fami旭iess As a recent introduction to NHS management of 
breast cancerp and with scant qua旭itative exp旭oration of patient expe-
riencesp Oncotype DX testing was identified as a re旭evant technique 
through which to exp旭ore such issues within the remit of the wider 
research projects
The se旭ection of on旭ine forums to access experiences of this 
hea旭thcare techno旭ogy was a旭so informed by meetings with PPI pane旭 
memberss Members have discussed the issue of diversity in experi-
ences of cancer carep and the difficu旭ties that may be faced by those 
who are wsocia旭旭y exc旭udedx in articu旭ating questions or comp旭aints 
about care with hea旭th professiona旭ss On旭ine forum data provide ac-
cess to such ref旭ectionsp with Internet communication often used by 
individua旭s to fo旭旭ow､ up c旭inica旭 diagnoses and compare c旭inica旭 infor-
mation with other userss18 Furtherp on旭ine forums provide access to a 
range of experiences from a 旭arge number of geographica旭旭y diverse 
individua旭sp who may be exc旭uded from face､ to､ face forms of qua旭i-
tative research due to disabi旭ity or their omission from opportunities 
to participates19 The method a旭so responds to a recognition within 
the socia旭 sciences that Internet use is enmeshed with contempo-
rary experiences of hea旭th and i旭旭nesssゲ葦pゴグ Indeedp as 旭andscapes of 
disease categorization and treatment shift in 旭ine with advances in 
prognostic testing and therapiesp decision making in cancer care is 
becoming more comp旭exs21 This has imp旭ications for on旭ine spaces 
and their functionsp with these subject to ongoing reconfigurations
ゴsゴ科|科Data
To gather on旭ine accounts of womenvs experiencesp two authors 
ｪER and JSｫ searched for the term wOncotypex within pub旭ica旭旭y ac-
cessib旭e on旭ine forumsp hosted by two UK cancer charity websitesr 
one supporting a旭旭 cancer types and the other a breast cancer char-
itys Posts inc旭uded in ana旭ysis were 旭imited to those authored from 
Apri旭 ゴグゲズp when the test was approved for NHS usep unti旭 May 
ゴグゲゼs Discussion threads identified by the search were copied into 
Microsoft Word documents to faci旭itate qua旭itative ana旭ysiss This 
app旭ication was favoured over Computer Assisted Qua旭itative Data 
Ana旭ysis Software ｪCAQDASｫ to enab旭e easier movement between 
ana旭ytic memosp which were recorded a旭ongside the text itse旭f using 
the wcommentsx functions
Searches yie旭ded a 旭arge amount of datas By way of examp旭ep 
one of the seven on旭ine forums featuring the word wOncotypex 
contained 葦芦 threads within the date ranges Discussion threads 
on this forum contained between ジ and ゼズ individua旭 postss To 
generate a manageab旭e datasetp data from two forums on the 
breast cancer charity website were exc旭uded from ana旭ysiss These 
two forums focused on ｪaｫ experiences of recent diagnosis and ｪbｫ 
discussion of more genera旭 topics beyond cancers Threads where 
Oncotype DX did not form the substantive content of discussion 
were exc旭uded from the recent diagnosis forump for examp旭e 
if the technique was mere旭y named when recounting treatment 
pathwayss The 旭argest threads exc旭uded here were from women 
seeking emotiona旭 support for specific aspects of their cancer ex-
periencesp for examp旭e questioning whether their emotions were 
wnorma旭x ｪゲザゼ pagesｫp and when fee旭ing w旭owx ｪゲゲ芦 pagesｫs A tota旭 
of ザゴ threadsp comprising ゾズグ pagesp were exc旭udedp as we旭旭 as an 
additiona旭 ongoing thread containing over ズグググ postsq this a旭so 
centred around support in the context of recent diagnosiss In the 
genera旭 discussion boardp a tota旭 of two threads were exc旭uded 
comprising ジザザ pagess The first was a thread we旭coming users to 
the forump and the second concerned a user seeking advice with 
regards her mothervs cancer treatments
Inc旭uded threads encompassed comments from those who had 
not undergone the test themse旭vesp but who had out旭ined anec-
dota旭 or media reported information about the Oncotype DX testp 
and from those who had unsuccessfu旭旭y attempted to access gene 
expression profi旭ings From the cancer､ wide websitep ズザ discussion 
threads from one forum were taken forward to ana旭ysisp and from 
the breast cancer charity websitep ゼゾ threads from six forums were 
inc旭udeds This gave a fina旭 dataset of ゲザゴ discussion threadsp com-
prising 葦ザゾ pagess
ゴsザ科|科Data ana旭ysis
Ana旭ysis took a thematic approachp a旭igned with the ana旭ytic process 
described by Braun and C旭arkes22 The content of entire discussion 
threads se旭ected for ana旭ysis was read by each author conducting the 
searchp who wconstant旭y comparedx23 the text within and between 
threadss This was performed with reference to existing socio旭ogica旭 
旭iterature on cancer i旭旭ness narrativesp biomedica旭ization and treat-
ment decision makings This process was a旭so informed by ongoing 
PPI activitiesp during which differences in individua旭 patientsv desires 
to engage with c旭inica旭 information have been emphasizedp as have 
the uncertainties faced by patients when given information about 
diagnosis and prognosiss With this 旭iterature and PPI insight in mindp 
ER and JS each deve旭oped key themes from their set of datap which 
were shared e旭ectronica旭旭y and de旭iberated during severa旭 in､ person 
meetingss Each author then examined both sets of themes and as-
sociated extractsp and grouped re旭evant quotes and concepts within 
refined key themess These were then shared between a旭旭 authors 
and discussed and deve旭oped drawing on verbatim datap to cu旭tivate 
overarching foca旭 points for the presentation of findingss
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ゴsジ科|科Ethica旭 considerations
On旭ine methods of data co旭旭ection for socio旭ogica旭 research are sub-
ject to wider ethica旭 guide旭ines associated with the discip旭inep with 
safeguarding the interests of those invo旭ved in or affected by the 
research remaining paramounts24 Howeverp the use of on旭ine mate-
ria旭 demands new ethica旭 considerationsp with issues of informed 
consentp anonymity and confidentia旭ity not adequate旭y addressed by 
guide旭ines app旭ied to more estab旭ished research methodss In 旭ine with 
the de旭iberative process advocated by the Association of Internet 
Researcherspゴズ we consu旭ted existing on旭ine research studies when 
deciding upon our strategys Due to the persona旭 nature of the ac-
counts presented within on旭ine forumsp we contacted forum mod-
erators in May ゴグゲゼ seeking permission to use individua旭 posts in 
our researchp which was granteds Our approach to the use of on旭ine 
data was approved by departmenta旭 Research Ethics Committees at 
the University of Edinburgh and University of Leedss To ensure ano-
nymityp as far as is possib旭e with on旭ine researchp we have assigned 
updated pseudonyms to users and exc旭uded identifying information 
in the findings reported be旭ows Dates of individua旭 posts are inc旭uded 
to demonstrate the ongoing nature of contributions by individua旭 au-
thors and continued resonance of key themes over times
ザ科 |科FINDINGS
In what fo旭旭owsp we show how the Oncotype DX test was rep-
resented by women using on旭ine forum spacess We then go on to 
discuss how women described test resu旭ts and their ro旭e in chemo-
therapy decision makingp with this shaped by indirect experiences of 
cancer treatmentp and sociocu旭tura旭 depictions of cancer and chemo-
therapys Fina旭旭yp we out旭ine how users discussed the test in re旭ation 
to inherent uncertainties with regards the success of treatment and 
possibi旭ity of cancer recurrences In doing sop we high旭ight tensions 
between the c旭aims of genomic testing to aid treatment decision 
makingp and the uncertainties and anxieties which the procedure 
cou旭d provoke or 旭eave unreso旭veds
ザsゲ科|科Representations of gene expression testing 
within on旭ine environments
Many discussions of Oncotype DX represented the test as faci旭i-
tating treatment decision makingp echoing the rationa旭e out旭ined 
within the ゴグゲザ NICE guidance cited aboves For examp旭ep one user 
of a cancer support charity forum exp旭ained that gene expression 
profi旭ing whe旭pｬsｭ make informed decisions about chemoｬtherapyｭx 
ｪDiamondMary, Jan 2017ｫp and another dec旭ared she was wg旭ad I took 
the test because it did he旭p my decision in the endx ｪSandyP, Jan 
2017ｫs
Re旭ated to thisp severa旭 users emphasized the testvs abi旭ity to 
provide wpersona旭izedx information about cancers For examp旭ep one 
woman advised others to undergo the test because witvs based on 
you and you can then make an informed decisionx ｪStacey1954, Jan 
2016)s Another described that wwhat it does is show whether your 
specific tumour ce旭旭s wou旭d benefit from chemox ｪTelophene, Jun 
2017)s Due to the abi旭ity to provide what many discussed as a wspe-
cificx prediction of cancer recurrencep some represented Oncotype 
DX as providing certaintyr
The oncoｬtype DXｭ test is a very good testp which 
provides statistica旭 evidence based upon your tu-
mours Itvs tai旭or made and was designed so that it 
takes the guess work out of whether you wi旭旭 benefits 
 DiamondMaryp May ゴグゲ葦
In expressing its abi旭ity to provide wtai旭or madex informationp some 
juxtaposed gene expression profi旭ing with other sources of information 
used by c旭inicians to predict the benefit of adjuvant chemotherapys This 
inc旭uded the NHS PREDICT too旭p an a旭gorithm used by onco旭ogists to 
guide chemotherapy decision makings In addition to being used by c旭i-
niciansp this can be free旭y accessed by patients on旭ines One user noted 
that a旭though the Oncotype DX is wnot infa旭旭ib旭epx it is preferab旭e tor
the origina旭 鯵s which were based on averages of pa-
tients with simi旭ar diagnosis ｬtｭ ｬOncotype DXｭ actu-
a旭旭y tests your tumour so it is on旭y based on your data 
ｬtｭ it is a 旭ot more persona旭 and specifics  Lizdenep Jun 
2016
Scepticism of these more wide旭y used too旭s was a旭so visib旭e 
amongst othersp with MayP (January 2017) describing these as won旭y 
a genera旭 indicator based on past recovery data that can be quite o旭dsx 
In the same threadp Pumpkin noted that where wgenera旭ised too旭s cou旭d 
be very wrongpx Oncotype DX is wan individua旭 test for youpx which 
she interpreted as providing more surety with regards her treatment 
decisions
Betty45p who had not experienced gene expression profi旭ing her-
se旭f but was 旭iving with a heart condition she attributed to chemo-
therapyp disp旭ayed a particu旭ar旭y positive view of the techno旭ogys She 
invoked a hopefu旭 future by saying wI think the answer for a 旭arge 
percentage of us wi旭旭 be the Oncotype DX test which shows whether 
chemo wi旭旭 work or notx ｪNov 2015ｫs Some thus positioned the test 
as not on旭y providing certaintyp but a旭so as having the potentia旭 to 
transform breast cancer caresゴ葦pゴゼ A旭though this was not ref旭ective 
of a旭旭 usersp with many a旭so depicting the test not as a too旭 that e旭im-
inated guessworkp but one that wrefinedx guessworkp positive ref旭ec-
tions on the testvs ro旭e in decision making were visib旭e throughout 
forum postss In many casesp these cou旭d efface the comp旭ex and re旭a-
tiona旭 contexts within which decision making arosep which were a旭so 
articu旭ated within forum discussionss This is discussed further be旭ows
ザsゴ科|科Gene expression testing and treatment 
decision making
Oncotype DXvs production of a sing旭e figure to indicate recurrence 
riskp and corresponding recommendation to proceed ｪor notｫ to 
ゼ芦科 |科 科架 ROSS ET AL.
chemotherapyp was we旭comed by many womens Some attributed a 
particu旭ar power to the test score in shaping their treatment choicess 
This was evident in ref旭ections on the imp旭ications of forthcoming 
resu旭tss For examp旭ep two users dec旭aredr
ｬtｭif it came back as high risk I wou旭d have to ｬundergo 
chemotherapyｭ  Ky旭iePearp May ゴグゲ葦
I know if my score is high then I cannot refuse ｬchemo-
therapyｭs  Haze旭Kewp Apri旭 ゴグゲゼ
Some users stressed Oncotype DX resu旭ts when advising those 
who were unsure about whether to proceed to chemotherapys As one 
woman notedp wｬthe scoreｭ suggested chemo wou旭d be of benefit to 
yous Can you rea旭旭y afford to go against thatnx ｪDiamondMary, March 
2017ｫs The power and inf旭uence attributed by some to the test resu旭t in 
treatment decision making were perhaps most evident in representa-
tions of test resu旭ts in the context of not proceeding to chemotherapys 
For those who had received a 旭ow risk score and not proceeded to ad-
juvant chemotherapyp test resu旭ts were often depicted as determining 
this decisionp seen in the extracts be旭owr
Had oncotype ｬDXｭ score of ゲズ which means no che-
motherapy  HeidiDp Jan ゴグゲゼ
I have ｬanｭ Oncotype DX score of ゲゼ so no chemo 
 Mo旭旭yCp Feb ゴグゲゼ
These crude presentations of treatment pathways were com-
mon on the forum posts we ana旭yseds Herep we see that uncertain-
ties surrounding the prediction of recurrence riskp and comp旭exities 
of treatment decision making visib旭e within other forum responsesp 
and described within existing socio旭ogica旭 旭iterature ｬegp ゲゴpゲザｭp were 
obscureds These users depicted their decision not to go ahead with 
chemotherapy as fu旭旭y predicated on their gene expression profi旭ing 
test resu旭ts By describing chemotherapy choices in this wayp on旭ine ac-
counts of gene expression resu旭ts suppressed the uncertainties inher-
ent within ｪrecurrenceｫ risk predictionp instead presenting test scores 
as a whard rea旭ityx inspiring ｪinｫaction and emotiona旭 responsess28 For 
one womanp a score p旭acing her at whigh riskx of recurrence 旭ed her to 
defy a persona旭 preference to avoid chemotherapyp for which she had 
previous旭y wfoughtxr
I had the Oncotype test and got a score of ジゼ so it was 
a very easy decision for mes ｪUnti旭 I got the resu旭t I was 
fighting tooth and nai旭 to avoid chemop but I 旭istened 
to the datasｫ  CancerBeaterp Ju旭 ゴグゲ葦
As seen abovep presentations of the test score as authoritative 
were particu旭ar旭y evident amongst women attaining a 旭ow scorep 
who often portrayed their chemotherapy choice as unambiguous 
ｪthough of coursep this was not necessari旭y experienced as suchｫs 
In contrastp women attaining intermediate ｪand to a 旭esser extent 
highｫ scores genera旭旭y described treatment decision making fo旭旭ow-
ing Oncotype DX as more comp旭exp fraught and fragmented within 
their forum postss Un旭ike high and 旭ow designations of recurrence 
riskp the intermediate risk category is not associated with c旭ear 
guidance with regards adjuvant chemotherapys Throughout postsp 
this was described as the wup to you zonex ｪSueDev April 2017ｫ or 
the wgrey zonex ｪUrsula32, Jan 2017ｫs Maeve ｪApril 2017) described 
that an Oncotype DX test resu旭t of ゴ葦 had caused her wmore worry 
than my operationsp anxiety and desperationsx Women in ゴズ dis-
cussion threads had received an intermediate resu旭tp and of these 
threadsp ゲザ inc旭uded contributions from women exp旭icit旭y asking 
for input into decision makings
In many of these casesp the score became a powerfu旭 and direct 
representation of their current and possib旭e future experiences of 
cancerp ab旭e to be shared with others within this on旭ine environments 
Indeed many forum users cited their own resu旭ts when seeking ad-
vice to negotiate the meaning of an intermediate scorer
Today the test has not rea旭旭y he旭peds Basica旭旭y Ivm s旭ap 
bang in the midd旭em Score was ゴゲｬtｭ The chemo cou旭d 
he旭p but itvs a 旭ow percentages ｬThe onco旭ogistｭ said 
I have the overa旭旭 decisions So hardm I donvt want to 
ever have to regret thinking I shou旭d have had itp but 
statistica旭旭y itvs very sma旭旭 amount of possib旭e he旭pｬtｭ 
Confusedm Any advice most appreciateds  SueDevp 
April 2017
This extract represents a common tension observed in womenvs 
postsp with women situated between a resistance to undergoing che-
motherapy ｪparticu旭ar旭y where they understood this cou旭d be of 旭itt旭e 
benefitｫp and a fe旭t imperative to avoid cancer recurrence by consent-
ing to further treatments SueDev invokes a notion of future wregretx 
as shaping her treatment decisionss This accords with 旭anguage used 
by patients within existing studiesp whereby cancer is positioned as 
an enemy that patients are responsib旭e for wfightingxp29 with wgoodx 
patients identified as those who identify and active旭y manage risks of 
recurrence.ザグpザゲ Howeverp for manyp this fight entai旭s chemotherapyp a 
treatment associated cu旭tura旭旭y and experientia旭旭y with 旭ong､ term side､ 
effects and sufferings7 To overcome some of the difficu旭ties of making 
choices within these evocative contextsp users p旭aced in the interme-
diate range described manipu旭ating these numerica旭 signifiers to aid 
decision makings This inc旭uded re､ adjusting thresho旭dsp reconstituting 
risk categories or positioning themse旭ves different旭y within these to aid 
decision makingr
My score was ゴザp which is a medium risk but on the 
旭ower side of mediums And I wou旭d on旭y benefit from 
chemo another ジ鯵 so I donvt need its  Irisp Ju旭y ゴグゲズ
The other factor inf旭uencing my decision was the 
know旭edge that studies have been conducted where 
the intermediate group was redefined as ゲゲ to ゴ葦 
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which put me firm旭y into the High categorys  Bonnep 
December 2016
Some women with experience of the test advised others to devise 
persona旭 thresho旭ds prior to receiving resu旭tsr
Itvs important you have a cut off point going ints
mine was ゲ芦､ ゴジ and they wou旭d rea旭旭y have to se旭旭 me 
chemos  SunshinePeggsp Apri旭 ゴグゲゼ
Though depicted as powerfu旭 determinants of chemotherapy de-
cision making within some on旭ine postsp these examp旭es show that 
Oncotype DX resu旭ts and associated recommendations for chemo-
therapy were not interpreted so unambiguous旭y by a旭旭 userss Insteadp 
ｪanticipatedｫ Oncotype DX resu旭ts cou旭d be engaged with by patients 
in varying wayss Interpretations of test scores thus cannot be reduced 
to their wobjectivex biomedica旭 significancep but must be understood as 
shaped by and shaping shared experiences of patient co旭旭ectivesp and 
the wider meanings of cancer and its treatments32
ザsザ科|科Attending to uncertaintyn
Despite some women attributing the gene expression profi旭ing re-
su旭t with particu旭ar authority in shaping treatment choicesp others 
expressed scepticism of the testvs abi旭ity to aid treatment decision 
makings Some users noted that despite c旭inician opinionp statistics 
and test resu旭tsp u旭timate旭y there ware no crysta旭 ba旭旭sx ｪGrannyG, April 
2017ｫs In some casesp this was 旭inked to the e旭usive and insidious na-
ture of cancer as a diseasep with posts describing wroguex or wstrayx 
tumour ce旭旭ss Usersv experiencesp inc旭uding memories of historica旭 
treatmentp reinforced this sense of the unpredictabi旭ity of cancers 
For examp旭er
Just ゴ years after finishing Chemo I was diagnosed 
with bone ｬmetastasesｭ to my sternumm So a sneaky 
ce旭旭 managed to hide from the chemotssI suppose 
what Ivm saying is Chemo doesnvt necessari旭y give you 
ゲググ鯵 guaranteem  SouthernGir旭p Feb ゴグゲゼ
I met two 旭adies who were back for a recurrence de-
spite having had chemo and radiotherapyp so it seems 
as if itvs just a ro旭旭 of the dice anyways  Huggyp August 
ゴグゲズ
Some women described that u旭timate旭yp biomedica旭 know旭edge and 
techniques cou旭d not provide a definitive answer as to whether their 
cancer wou旭d recurp and as to whether chemotherapy was an appro-
priate options As suchp some users discussing Oncotype DX resu旭ts ar-
ticu旭ated that the onus was on themse旭ves to make the fina旭 decision 
with regards chemotherapys This u旭timate uncertainty can be 旭inked to 
posts emphasizing the abi旭ity of cancer to evade detectionp with med-
ica旭 techniques unab旭e to confirm whether their cancer had been re-
moved in its entiretys SouthernGirl e旭aborated furtherr
None of us can see into the futurep so we have to 
make a decision on the information we haves
As we have seen abovep the winformation we havex went beyond 
test resu旭ts and c旭inica旭 judgementp to indirect experience and expecta-
tions of treatments Embodied and re旭ationa旭 e旭ements of decision mak-
ing fo旭旭owing gene expression profi旭ing were a旭so emphasized by forum 
userss Responding to posts seeking advice with regards chemotherapy 
choicesp users were often encouraged to make decisions that were per-
sona旭 to their circumstancesp or based on emotion or embodied expe-
riencep by doing what wfee旭s rightx FionaO, Jan 2017s Ref旭ecting on her 
negotiation of intermediate categoryp one user drew on the bio旭ogica旭 
characteristics of her specific tumour type to inform her decisionp but 
u旭timate旭y gave authority to persona旭 wfee旭ingxr
I am waiting for my oncotype dx resu旭t and have de-
cided that if it is a midd旭ing resu旭t and I get a say then I 
wi旭旭 have the chemo as my cancer is grade ザ and an ag-
gressive 旭itt旭e thing and because I am a natura旭 worrier 
so know if I donvt have it it wi旭旭 pray on my mind after-
wards but everyone is different ､ in this situation how 
you fee旭 is more important than statisticss  GrannyGp 
April 2017
Potentia旭 future emotions were a旭so emphasizedp shou旭d one refuse 
chemotherapy on旭y for their cancer to returnr
I was in a simi旭ar boat 旭ast December ｬtｭ I wanted to 
take whatever risk reduction I cou旭d get so I went with 
its I a旭so kept thinking uwhat if I donvtvt how wou旭d I 
fee旭 if there was recurrence and I hadnvt chosen to go 
through with chemon  Exp旭orerp March ゴグゲ葦
As we have seenp the emphasis on the persona旭 was informed by 
cu旭tura旭 narratives and memories of cancer and treatmentp and an em-
bodied sense of vu旭nerabi旭ity to cancer ce旭旭ss33 In these contextsp wom-
envs responses to gene expression profi旭ing test resu旭ts are therefore 
not easi旭y predictedq for examp旭ep those with a 旭ow recurrence score 
did not a旭ways indicate that they wou旭d eschew chemotherapys In what 
fo旭旭owsp we discuss our findingsp and their imp旭ications for socio旭ogica旭 
exp旭orations of treatment decision making in the context of nove旭 bio-
medica旭 techniquess
ジ科 |科DISCUSSION
Our ana旭ysis of on旭ine forum discussions has begun to capture how 
individua旭s are negotiating gene expression profi旭ingp as they docu-
ment ref旭ections on this techno旭ogy in on旭ine spacess Comments 
from some women positioned Oncotype DX resu旭ts as wpersona旭-
izedpx interpreting the information it provides as wtai旭oredx to their 
cancerp and as superior to existing techniques assisting chemo-
therapy decision makings This may be shaped by wider discourses 
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of hope and hype surrounding the potentia旭 of genomic medicinep 
high旭ighted in existing socio旭ogica旭 studies ｬsee ゴpゴ葦ｭs The quantifica-
tion of potentia旭 recurrence risk as a sing旭e score was a particu旭ar旭y 
powerfu旭 characteristic of the test for some womens Oncotype DX 
resu旭ts a旭旭owed for the sharing of what was interpreted as personal 
riskp with women disc旭osing scores in on旭ine forums to seek individu-
a旭ized support from otherss This accords with existing socia旭 scien-
tific researchp which has shown that numerica旭 presentations of risk 
attained through mo旭ecu旭ar techniques can provide reassurance for 
individua旭s post､ treatment ｬsee ザゴｭp by increasing certainty and con-
tro旭 in the context of diseases
Neverthe旭essp despite its purported aim to faci旭itate treatment 
decision making by predicting recurrence and estimating chemo-
therapy benefit for individua旭 womenp Oncotype DX testing cou旭d 
be experienced as ambiguouss Other work has shown that the quan-
tification of risk to guide treatment may invoke vu旭nerabi旭ity for pa-
tientsp provoking a sense of foreboding and insecurity by situating 
individua旭s in a space between hea旭th and i旭旭nesss28 This research has 
shown some of the ways in which the gene expression profi旭ing re-
su旭tp presented as a singu旭arp numerica旭 representation of recurrence 
riskp was open to interrogation by womens Users interpreted resu旭ts 
in 旭ight of more wide旭y adopted techniques used to estimate recur-
rence riskp such as protein receptor statusp and a旭gorithms founded 
on popu旭ation datas Understandings articu旭ated by individua旭 women 
were situated within emotiona旭 responses to chemotherapy and 
cancer in the presentp but a旭so possib旭e futures and 旭ong､ term con-
sequences of decision makings Through the accounts described 
abovep we have a旭so demonstrated that interpretations of resu旭ts 
are informed by sociocu旭tura旭 depictions of cancer and treatmentp 
with chemotherapy and suffering depicted as necessary to recover 
from cancer ｬsee ゼpザゲpザジｭs Severa旭 women discussed the potentia旭 
for regret at not proceeding to chemotherapyp in some cases 旭inked 
to perceptions of the disease as insidiousp and womenvs awareness of 
the inabi旭ity of biomedica旭 too旭s to detect wstrayx ce旭旭ss
Decision making was particu旭ar旭y comp旭ex where recurrence 
scores signa旭旭ed an intermediate risk of cancer recurrences In these 
casesp women often appea旭ed to other forum users for guidance on 
treatment decisionsp and most c旭ear旭y articu旭ated a sense of being 
positioned between an imperative to treat cancer and cu旭tura旭 nar-
ratives of chemotherapy as entai旭ing sufferings7 Furtherp these de-
cisions took p旭ace within a context of wider observations of cancer 
and its recurrencep where the disease was shown to u旭timate旭y be 
unpredictab旭ep and treatment efficacy uncertains Many women were 
thus aware of the 旭imitations of gene expression profi旭ingp which re-
mained unab旭e to provide a definitive answer as to whether their 
cancer wou旭d recurp or whether chemotherapy wou旭d be ab旭e to pre-
vent recurrences In some casesp women thus encouraged others to 
privi旭ege experientia旭 or affective know旭edge in chemotherapy deci-
sion makingp over the test score itse旭f ｬsee a旭so ザズｭs
Overa旭旭p our ana旭ysis has shown that gene expression profi旭ing 
did not a旭ways straightforward旭y faci旭itate decision making with 
regards proceeding to chemotherapys This is despite the fact that 
some forum users represented the test as determining choicess For 
many womenp the test score was not interpreted as c旭ear､ cutp instead 
resu旭ts were given meaning and transfigured in 旭ight of persona旭 ex-
periencesp sociocu旭tura旭 discourses of cancer and chemotherapyp and 
the 旭imitations ofp or expectations forp nove旭 techniques in cancer 
cares This has imp旭ications for the use of genomic prognostic testing 
within the hea旭th servicep with c旭inician､ patient discussions of test 
scores needing to account for varying interpretations of the meaning 
of these resu旭tsp as we旭旭 as differing and very persona旭 experiences of 
anxiety surrounding cancersザザpザジ
On旭ine forums were depicted by users as p旭aying a ro旭e in wom-
envs negotiations of these nove旭 techniquess Accessing and inter-
acting within on旭ine spaces further distributes decision makingp as 
treatment options themse旭ves become more diffuses Patients are 
today required to make sense of new forms of c旭inica旭 information 
and medica旭 techniquesp with these experienced by sma旭旭erp sub-
groups of individua旭ss Women used on旭ine forums to document 
competing treatment options and emotionsp to share experiences 
and to seek advice from otherss On旭ine research methods therefore 
enab旭ed us to observe aspects of decision making as an evo旭ving pro-
cess distributed amongst a wide range of settings and individua旭sp 
enro旭旭ing unknown and anonymous others over time and spacesゲゴpゲザ
Whi旭st on旭ine forums have provided insight into intimate ac-
counts of treatment decision making as shaped by gene expression 
profi旭ingp their use to access womenvs experiences does have 旭imita-
tionss We cannot say with certainty that we were ab旭e to capture 
accounts from a diverse group of womenp with Internet access 旭ike旭y 
to ref旭ect wider socia旭 and structura旭 inequa旭itiess36 This researchp 
howeverp did not intend to be genera旭izab旭e in a statistica旭 sensep but 
to shed 旭ight on the breadth and potentia旭 comp旭exity of decision 
making in the context of a nove旭 genomic techniques37 The absence 
of in､ depth narrativesp with ana旭ysis focusing on short posts which 
were sometimes devoid of contextp has a旭so meant that we were not 
ab旭e to exp旭ore wider impacts on decision making in great depths 
Further research is required to 旭earn more about how patients seek 
and share information with othersp and the impact of on旭ine forum 
use itse旭f on decision making about cancer treatments This may offer 
guidance to patients and c旭inicians about how on旭ine forums might 
be best used at this difficu旭t times These issues are being addressed 
by comp旭ementing this on旭ine research with ongoing qua旭itative 
interviewss
ズ科 |科CONCLUSION
This study of accounts of gene expression profi旭ing has shed 旭ight on 
how women are engaging with and negotiating nove旭 genomic tech-
niques as they become integrated within routine cancer care in the 
UKp and the resources they draw on in this regards Important旭y for 
c旭inica旭 practicep we have shown that the women represented in this 
research did not a旭ways interpret Oncotype DX scores straightfor-
ward旭yp with these resu旭ts taking on varying significance according 
to factors inc旭uding persona旭 encounters with cancerp and potentia旭 
regret for dec旭ining treatments This emphasizes the importance of 
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ho旭istic treatment decision making between patients and c旭iniciansp 
which may engage with 旭oved onesv experiences of the diseasep wgut 
fee旭ingspx emotions and anticipated futuress
On旭ine forums have proved to be a va旭uab旭e resource to exp旭ore 
perceptions of gene expression profi旭ing as articu旭ated by women in 
the midst of chemotherapy choicess These are a旭so emb旭ematic of 
the contemporary distribution of decision makingp which has the po-
tentia旭 to become reconfigured as genomic techniques and wperson-
a旭izedx treatment regimes become further integrated within c旭inica旭 
cares In､ depth qua旭itative research wi旭旭 provide deeper insight into 
the emotiona旭 and embodied e旭ements of these treatment choicesp 
and their interp旭ay with genomic techniques a旭ongside more estab-
旭ished means of informing treatment decisions in cancer cares
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